An observational study in Hemophilia A With Inhibitors, sponsored by Skane University Hospital. Completed at 1 site in Sweden. Open to male participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2005-10-04.
Sponsored by Skane University Hospital · Observational
Existing data support the concept that a genetic predisposition for inhibitor development exists. The aim of the Malmö International Brother Study (MIBS) is to evaluate genetic factors associated with the development of inhibitory antibodies in patients with hemophilia.
Inhibitory antibodies to factor VIII develop in 10-15% of all patients with hemophilia A and in 25-30% of patients with the severe form of the disease after exposure to factor VIII concentrates. Both genetic and environmental risk factors for inhibitor development have been evaluated, but in most cases without consistent results. Among the genetic factors, an association between large rearrangements of the factor VIII and IX genes and a higher risk for inhibitors has been described. However, a majority of patients with null mutations, including the intron 22 inversion, do not develop inhibitory antibodies. It is obvious that other genetic markers influencing the immune response to replacement therapy in patients with hemophilia remain to be identified and the aim of Malmö International Brother Study (MIBS) is to characterize these factors.
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →Skane University Hospital is the lead sponsor of 71 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
-Mild, moderate or severe hemophilia A or B and one or more brothers with mild, moderate or severe hemophilia A or B
Exclusion Criteria:
-Absence of sufficient information to classify inhibitor status
This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Skane University Hospital